TP53 and leukemia: In line with these data, it was recently suggested that inhibiting HIF1α with compounds like echinomycin may represent a new therapeutic opportunity to impair maintenance of the LSCs population, and this may be particularly relevant in the genetic background of TP53-mutated AMLs, where echinomycin showed a potent cytotoxic effect and affected leukemia propagation in xenograft mouse models (78).